Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.

about

Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.

Item

http://www.wikidata.org/entity/Q47769899

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@en

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@nl

type

Item

label

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@en

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@nl

prefLabel

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@en

Evolving Role of Non-Statin Th ...... on: Past, Present, and Future.

@nl

P1476

Evolving Role of Non-Statin Th ...... ion: Past, Present, and Future

@en

P2093

Lauren Pamulapati

http://www.w3.org/2001/XMLSchema#string

P2860

CETP Inhibition: Past Failures and Future Hopes

Simvastatin with or without ezetimibe in familial hypercholesterolemia

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.

PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.

Effects of combination lipid therapy in type 2 diabetes mellitus.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

P304

164-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1002/PHAR.2074

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29266309

http://www.w3.org/2001/XMLSchema#string

P921

statin therapy

dyslipidemias